Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?

Sabrina Rossi, Michele Basso, Antonia Strippoli, Giovanni Schinzari, Ettore D'Argento, Mario Larocca, Alessandra Cassano, Carlo Barone

Research output: Contribution to journalReview article

Abstract

Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes. In resectable early-stage CRC, high GPS scores seem significantly associated with cancer-specific survival. It has also been suggested that adjuvant chemotherapy for stage II CRC could improve cancer-specific survival in patients with high GPS scores. In patients with both resectable and unresectable metastatic CRC and a higher GPS score, all studies suggested poorer overall survival. In early-stage and resectable metastatic CRC, the NLR seemed related to overall survival; however, the data for disease-free survival were discordant. In metastatic disease, a possible correlation between a greater NLR and poorer response to bevacizumab has been suggested. Data concerning the prognostic and predictive role of the PLR and LMR in CRC are to date insufficient. In patients with unresectable metastatic disease, inflammation markers can be used to predict the chemotherapeutic outcome and monitor tumor progression. However, further prospective studies might lead to better risk stratification for patients eligible for curative surgery, thus, allowing the restriction of neoadjuvant and adjuvant therapy to patients with high-risk CRC.

Original languageEnglish
Pages (from-to)264-274
Number of pages11
JournalClinical Colorectal Cancer
Volume16
Issue number4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Colorectal Neoplasms
Inflammation
Lymphocytes
Neutrophils
Survival
Neoplasms
Monocytes
Blood Platelets
Neoadjuvant Therapy
Adjuvant Chemotherapy
Disease-Free Survival
Prospective Studies
Neoplasm Metastasis

Keywords

  • CRC
  • Glasgow prognostic score
  • Lymphocyte-to-monocyte ratio
  • Neutrophil-to-lymphocyte ratio
  • Platelet-to-lymphocyte ratio

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Rossi, S., Basso, M., Strippoli, A., Schinzari, G., D'Argento, E., Larocca, M., ... Barone, C. (2017). Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? Clinical Colorectal Cancer, 16(4), 264-274. https://doi.org/10.1016/j.clcc.2017.03.015

Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? / Rossi, Sabrina; Basso, Michele; Strippoli, Antonia; Schinzari, Giovanni; D'Argento, Ettore; Larocca, Mario; Cassano, Alessandra; Barone, Carlo.

In: Clinical Colorectal Cancer, Vol. 16, No. 4, 01.12.2017, p. 264-274.

Research output: Contribution to journalReview article

Rossi, S, Basso, M, Strippoli, A, Schinzari, G, D'Argento, E, Larocca, M, Cassano, A & Barone, C 2017, 'Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?', Clinical Colorectal Cancer, vol. 16, no. 4, pp. 264-274. https://doi.org/10.1016/j.clcc.2017.03.015
Rossi S, Basso M, Strippoli A, Schinzari G, D'Argento E, Larocca M et al. Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? Clinical Colorectal Cancer. 2017 Dec 1;16(4):264-274. https://doi.org/10.1016/j.clcc.2017.03.015
Rossi, Sabrina ; Basso, Michele ; Strippoli, Antonia ; Schinzari, Giovanni ; D'Argento, Ettore ; Larocca, Mario ; Cassano, Alessandra ; Barone, Carlo. / Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?. In: Clinical Colorectal Cancer. 2017 ; Vol. 16, No. 4. pp. 264-274.
@article{d8edb913d72a4f13ac4b8a186b2c6a56,
title = "Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?",
abstract = "Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes. In resectable early-stage CRC, high GPS scores seem significantly associated with cancer-specific survival. It has also been suggested that adjuvant chemotherapy for stage II CRC could improve cancer-specific survival in patients with high GPS scores. In patients with both resectable and unresectable metastatic CRC and a higher GPS score, all studies suggested poorer overall survival. In early-stage and resectable metastatic CRC, the NLR seemed related to overall survival; however, the data for disease-free survival were discordant. In metastatic disease, a possible correlation between a greater NLR and poorer response to bevacizumab has been suggested. Data concerning the prognostic and predictive role of the PLR and LMR in CRC are to date insufficient. In patients with unresectable metastatic disease, inflammation markers can be used to predict the chemotherapeutic outcome and monitor tumor progression. However, further prospective studies might lead to better risk stratification for patients eligible for curative surgery, thus, allowing the restriction of neoadjuvant and adjuvant therapy to patients with high-risk CRC.",
keywords = "CRC, Glasgow prognostic score, Lymphocyte-to-monocyte ratio, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio",
author = "Sabrina Rossi and Michele Basso and Antonia Strippoli and Giovanni Schinzari and Ettore D'Argento and Mario Larocca and Alessandra Cassano and Carlo Barone",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.clcc.2017.03.015",
language = "English",
volume = "16",
pages = "264--274",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?

AU - Rossi, Sabrina

AU - Basso, Michele

AU - Strippoli, Antonia

AU - Schinzari, Giovanni

AU - D'Argento, Ettore

AU - Larocca, Mario

AU - Cassano, Alessandra

AU - Barone, Carlo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes. In resectable early-stage CRC, high GPS scores seem significantly associated with cancer-specific survival. It has also been suggested that adjuvant chemotherapy for stage II CRC could improve cancer-specific survival in patients with high GPS scores. In patients with both resectable and unresectable metastatic CRC and a higher GPS score, all studies suggested poorer overall survival. In early-stage and resectable metastatic CRC, the NLR seemed related to overall survival; however, the data for disease-free survival were discordant. In metastatic disease, a possible correlation between a greater NLR and poorer response to bevacizumab has been suggested. Data concerning the prognostic and predictive role of the PLR and LMR in CRC are to date insufficient. In patients with unresectable metastatic disease, inflammation markers can be used to predict the chemotherapeutic outcome and monitor tumor progression. However, further prospective studies might lead to better risk stratification for patients eligible for curative surgery, thus, allowing the restriction of neoadjuvant and adjuvant therapy to patients with high-risk CRC.

AB - Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes. In resectable early-stage CRC, high GPS scores seem significantly associated with cancer-specific survival. It has also been suggested that adjuvant chemotherapy for stage II CRC could improve cancer-specific survival in patients with high GPS scores. In patients with both resectable and unresectable metastatic CRC and a higher GPS score, all studies suggested poorer overall survival. In early-stage and resectable metastatic CRC, the NLR seemed related to overall survival; however, the data for disease-free survival were discordant. In metastatic disease, a possible correlation between a greater NLR and poorer response to bevacizumab has been suggested. Data concerning the prognostic and predictive role of the PLR and LMR in CRC are to date insufficient. In patients with unresectable metastatic disease, inflammation markers can be used to predict the chemotherapeutic outcome and monitor tumor progression. However, further prospective studies might lead to better risk stratification for patients eligible for curative surgery, thus, allowing the restriction of neoadjuvant and adjuvant therapy to patients with high-risk CRC.

KW - CRC

KW - Glasgow prognostic score

KW - Lymphocyte-to-monocyte ratio

KW - Neutrophil-to-lymphocyte ratio

KW - Platelet-to-lymphocyte ratio

UR - http://www.scopus.com/inward/record.url?scp=85017407000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017407000&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2017.03.015

DO - 10.1016/j.clcc.2017.03.015

M3 - Review article

AN - SCOPUS:85017407000

VL - 16

SP - 264

EP - 274

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 4

ER -